NFKB1 and B-cell chronic lymphocytic leukemia: Consistent with the observations made with resiquimod in CLL-B cells (Figures 1 and 3), analysis of this database (GSE49853) by GSEA suggested TLR-activated B cells that do not make IL-10 exhibit much stronger NFκB activity (Figure 5C).